System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 41547246 DOI: 10.1016/j.jcv.2026.105913

Comparative performance of the Siemens Atellica and Abbott Architect assays for HBsAg quantification in patients with chronic hepatitis B or hepatitis Delta.

J Clin Virol 182:105913

Authors: Léonie Badot, Marie-Noëlle Hilleret, Dorra Guergour, Carole Chirica, Aurélie Truffot, Patrice Morand, Raphaële Germi, Caroline Scholtès, Sylvie Larrat, Julien Lupo

Affiliations

  • Université Grenoble Alpes, CHU Grenoble Alpes, Laboratoire de Virologie, Grenoble 38000, France.
  • Université Grenoble Alpes, CHU Grenoble Alpes, Service d'Hépato-Gastroentérologie, Grenoble 38000, France.
  • Université Grenoble Alpes, CHU Grenoble Alpes, Service de Biochimie, Biologie Moléculaire et toxicologie de l'environnement, Grenoble 38000, France.
  • Université Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), CHU Grenoble Alpes, Laboratoire de Virologie, Grenoble 38000, France.
  • Université Claude-Bernard Lyon 1 (UCBL1), Service de Virologie, Hospices Civils de Lyon (HCL), UMR PaTLiv, Lyon INSERM U1350, France.
  • Université Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale (IBS), CHU Grenoble Alpes, Laboratoire de Virologie, Grenoble 38000, France.

Abstract

BACKGROUND

Quantitative hepatitis B surface antigen (qHBsAg) is a routine marker for monitoring patients with chronic hepatitis B (CHB) or Delta (CHD). New commercially available assays require independent evaluation in clinical laboratories before being adopted for routine use. This study assessed the performance of the new Siemens Atellica IM Quantitative HBsAg (QHBs) assay in patients with CHB or CHD.

METHODS

Over a six-month period, all serum specimens from patients with CHB or CHD that were submitted to the laboratory for qHBsAg testing were prospectively analyzed using both the historically used Architect assay and the new Atellica assay. Furthermore, in a retrospective longitudinal analysis, we examined CHD patients who showed a reduction of at least 1 log 10 UI/mL in HBsAg levels over the course of treatment.

RESULTS

A total of 311 serum samples from 216 patients were prospectively evaluated. The Architect assay yielded slightly higher values than the Atellica assay (mean difference: +0.10 log₁₀ IU/mL). There was excellent agreement and correlation between the two assays (Spearman's Rs = 0.99; 95 % CI [0.9877-0.9922]). Three samples with low HBsAg concentrations (0.02-0.07 IU/mL) were detected by the Atellica assay but not by the Architect assay. In the longitudinal follow-up of five CHD patients (82 samples), both assays produced comparable results and could be used interchangeably without any potential clinical impact.

CONCLUSION

The Atellica assay demonstrated equivalent performance to the Architect assay for qHBsAg monitoring in patients with CHB or CHD.

MeSH

Hepatitis B Surface Antigens, Hepatitis D, Laboratories, Serum, Hepatitis, Chronic, Hepatitis B, Hepatitis B, Chronic, Hepatitis